Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.
Developer of chemical biology technologies designed to create therapeutics for untreatable diseases. The company's technology uses the power of covalent bonding and a proprietary technology platform for high-throughput drug discovery, enabling pharmaceutical developers to convert genetic discoveries into real drugs to treat cancer, Alzheimer's, infectious diseases, and even aging.
nTopology, Inc. develops engineering design software that enhances manufacturing processes. Its primary offering, nTopology, allows engineers to create lightweight and optimized parts tailored to functional requirements. The software integrates design, simulation, and advanced manufacturing into a cohesive workflow, addressing geometry bottlenecks and enhancing team collaboration. Key features include Lightweighting, Architected Materials, Topology Optimization, Additive Manufacturing, and Design Analysis. nTopology's tools enable precise control over spatial variations, facilitating a broader range of designs and effective utilization of analysis data. The company serves various industries, including aerospace and defense, medical, automotive, consumer products, and education. Founded in 2013 and based in New York, nTopology aims to redefine engineering design tools for advanced manufacturing.
GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.
nTopology, Inc. develops engineering design software that enhances manufacturing processes. Its primary offering, nTopology, allows engineers to create lightweight and optimized parts tailored to functional requirements. The software integrates design, simulation, and advanced manufacturing into a cohesive workflow, addressing geometry bottlenecks and enhancing team collaboration. Key features include Lightweighting, Architected Materials, Topology Optimization, Additive Manufacturing, and Design Analysis. nTopology's tools enable precise control over spatial variations, facilitating a broader range of designs and effective utilization of analysis data. The company serves various industries, including aerospace and defense, medical, automotive, consumer products, and education. Founded in 2013 and based in New York, nTopology aims to redefine engineering design tools for advanced manufacturing.
Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. The company integrates automation, machine learning, and genomics to enhance its platform, which aids in optimizing microbial strains and improving the efficiency of production processes. By leveraging big data and artificial intelligence, Zymergen collaborates with clients to engineer novel molecules from microbes, thereby advancing product development. Founded in 2013 and headquartered in Emeryville, California, Zymergen also has offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, enabling it to serve a global clientele effectively.
Atomwise, Inc. specializes in deep learning artificial intelligence technology aimed at small molecule drug discovery. The company leverages its proprietary AI platform, AtomNet, which contains over 16 billion molecules for virtual screening, to enhance the speed and accuracy of drug discovery processes. This technology employs a statistical approach to predict the binding of small molecules to proteins, aiding in drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise collaborates on numerous projects each year with major pharmaceutical and agrochemical companies, as well as over 200 universities and hospitals across 40 countries. Founded in 2012 and based in San Francisco, Atomwise was previously known as Chematria, Inc. before rebranding in 2015.
Atomwise, Inc. specializes in deep learning artificial intelligence technology aimed at small molecule drug discovery. The company leverages its proprietary AI platform, AtomNet, which contains over 16 billion molecules for virtual screening, to enhance the speed and accuracy of drug discovery processes. This technology employs a statistical approach to predict the binding of small molecules to proteins, aiding in drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise collaborates on numerous projects each year with major pharmaceutical and agrochemical companies, as well as over 200 universities and hospitals across 40 countries. Founded in 2012 and based in San Francisco, Atomwise was previously known as Chematria, Inc. before rebranding in 2015.
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.
Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.
Advano, operating under NanoStar, Inc., is a New Orleans-based company specializing in silicon nanotechnology. Founded in 2014, Advano develops and produces functionalized silicon nanoparticles and quantum dots for various applications. Notably, its products enhance the energy density of lithium-ion batteries by 30-40%, making them suitable for electric vehicles, consumer electronics, and IoT devices, all without compromising battery life or increasing costs. Additionally, Advano's technology is applied in CO2 carbon capture, super hydrophobic coatings, and printable electronics, serving industries such as telecommunications.
Novome Biotechnologies, Inc. is a biotechnology company based in South San Francisco, California, that specializes in engineering bacteria from the human gut to address chronic diseases. Founded in 2015, the company has developed a platform for the controlled colonization of the gut with genetically engineered bacteria, known as Genetically Engineered Microbial Medicines (GEMMs). This innovative approach allows for sustained therapeutic interventions through the precise delivery of microbial activities. Novome's lead preclinical program targets hyperoxaluria by creating a therapeutic strain of bacteria aimed at degrading oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology platform to explore additional therapeutic applications.
Novome Biotechnologies, Inc. is a biotechnology company based in South San Francisco, California, that specializes in engineering bacteria from the human gut to address chronic diseases. Founded in 2015, the company has developed a platform for the controlled colonization of the gut with genetically engineered bacteria, known as Genetically Engineered Microbial Medicines (GEMMs). This innovative approach allows for sustained therapeutic interventions through the precise delivery of microbial activities. Novome's lead preclinical program targets hyperoxaluria by creating a therapeutic strain of bacteria aimed at degrading oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology platform to explore additional therapeutic applications.
Novomer is a materials company focused on developing high-performance, eco-friendly plastics, polymers, and chemicals. Established in 2004 and based in Waltham, Massachusetts, the company leverages proprietary catalytic technology to convert carbon dioxide and other renewable materials into cost-effective industrial products. This innovative approach combines traditional chemical feedstocks with carbon, enabling the sustainable synthesis of a range of chemicals and materials. Novomer’s technology not only offers competitive pricing but also contributes to environmental sustainability by addressing global warming and climate change challenges through the use of carbon in industrial applications.
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.
X-37, LLC is a pharmaceutical discovery and development company based in South San Francisco, California, established in 2018. The company specializes in developing treatments for cancer, autoimmune diseases, and coagulation disorders. Utilizing advanced artificial intelligence technology from Atomwise, X-37 aims to discover novel drug candidates by screening extensive libraries of chemical compounds against significant pharmaceutical targets. This innovative approach enables the healthcare sector to expedite the discovery and development of new medicines, ultimately benefiting patients in need of effective therapies.
X-37, LLC is a pharmaceutical discovery and development company based in South San Francisco, California, established in 2018. The company specializes in developing treatments for cancer, autoimmune diseases, and coagulation disorders. Utilizing advanced artificial intelligence technology from Atomwise, X-37 aims to discover novel drug candidates by screening extensive libraries of chemical compounds against significant pharmaceutical targets. This innovative approach enables the healthcare sector to expedite the discovery and development of new medicines, ultimately benefiting patients in need of effective therapies.
Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. The company integrates automation, machine learning, and genomics to enhance its platform, which aids in optimizing microbial strains and improving the efficiency of production processes. By leveraging big data and artificial intelligence, Zymergen collaborates with clients to engineer novel molecules from microbes, thereby advancing product development. Founded in 2013 and headquartered in Emeryville, California, Zymergen also has offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, enabling it to serve a global clientele effectively.
GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.
GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.
X-37, LLC is a pharmaceutical discovery and development company based in South San Francisco, California, established in 2018. The company specializes in developing treatments for cancer, autoimmune diseases, and coagulation disorders. Utilizing advanced artificial intelligence technology from Atomwise, X-37 aims to discover novel drug candidates by screening extensive libraries of chemical compounds against significant pharmaceutical targets. This innovative approach enables the healthcare sector to expedite the discovery and development of new medicines, ultimately benefiting patients in need of effective therapies.
Atomwise, Inc. specializes in deep learning artificial intelligence technology aimed at small molecule drug discovery. The company leverages its proprietary AI platform, AtomNet, which contains over 16 billion molecules for virtual screening, to enhance the speed and accuracy of drug discovery processes. This technology employs a statistical approach to predict the binding of small molecules to proteins, aiding in drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise collaborates on numerous projects each year with major pharmaceutical and agrochemical companies, as well as over 200 universities and hospitals across 40 countries. Founded in 2012 and based in San Francisco, Atomwise was previously known as Chematria, Inc. before rebranding in 2015.
Nyriad Limited is a technology company that specializes in advanced storage solutions tailored for big data and high-performance computing. Established in 2015 and based in Cambridge, New Zealand, Nyriad develops innovative products such as NSULATE, an ultra-fast erasure coding solution; NPAC, which offers parallel accelerated compression for real-time storage and network traffic; and NAPPA, a framework that integrates various compression and encoding codecs into server and client applications. The company’s compression technology platform leverages graphics processing units (GPUs) to deliver resilient data storage, addressing the scale, security, efficiency, and performance requirements of demanding IT projects. Nyriad's offerings support both storage and computing performance, catering to the needs of systems integrators and organizations engaged in high-performance data-driven initiatives.
Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.
Macromoltek does computational drug discovery for pharma companies, focusing on antibodies for therapeutics and diagnostics. This mother-daughter team’s approach aims to make research for everything from flu to cancer treatments an order of magnitude faster. With an accelerated process to discover antibodies, medical researchers can (1) craft targeted treatment plans for previously undruggable targets and (2) overcome patients’ drug resistance, a major challenge when treating diseases caused by bacteria, viruses, and parasites.
Asimov, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in designing and developing genetically engineered therapeutics. The company utilizes a platform for molecular manufacturing, which incorporates machine-learning algorithms to connect large-scale biological datasets with mechanistic models. Asimov programs living cells with genetic circuits, enabling the creation of innovative biotechnologies in partnership with its customers. Their capabilities include the manufacturing of protein biologics, viral vectors, and cell and gene therapies. Founded in 2017, Asimov leverages a combination of computer-aided design, artificial intelligence, and synthetic biology to advance its mission.
nTopology, Inc. develops engineering design software that enhances manufacturing processes. Its primary offering, nTopology, allows engineers to create lightweight and optimized parts tailored to functional requirements. The software integrates design, simulation, and advanced manufacturing into a cohesive workflow, addressing geometry bottlenecks and enhancing team collaboration. Key features include Lightweighting, Architected Materials, Topology Optimization, Additive Manufacturing, and Design Analysis. nTopology's tools enable precise control over spatial variations, facilitating a broader range of designs and effective utilization of analysis data. The company serves various industries, including aerospace and defense, medical, automotive, consumer products, and education. Founded in 2013 and based in New York, nTopology aims to redefine engineering design tools for advanced manufacturing.
HelixNano is a biotechnology company focused on leveraging artificial intelligence and synthetic biology to develop innovative solutions for genetic diseases. Initially concentrating on cancer vaccines, the company is now pivoting to create COVID-19 vaccine candidates that prioritize precision and safety. HelixNano's platform enables the reliable expression of transgenes in humans, facilitating advancements in gene therapies and genome engineering. The company aims to not only address the current COVID-19 pandemic but also to develop vaccines that provide protection against all future coronaviruses. Through its work, HelixNano seeks to enable previously unattainable applications in both human and non-human biology, ultimately improving patient outcomes across a range of diseases.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, which allows for the precise reading and writing of DNA. Founded in 2013, the company targets multiple markets, including life sciences, industrial applications, information storage, nanotechnology, and DNA electronics. Its innovative approach is inspired by natural processes and focuses on producing long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner. The company boasts a strong executive and scientific team and holds an extensive intellectual property portfolio. It has garnered investments from various notable entities, highlighting its potential to advance products in industrial synthetic biology, personalized therapeutics, and precision diagnostics.
Advano, operating under NanoStar, Inc., is a New Orleans-based company specializing in silicon nanotechnology. Founded in 2014, Advano develops and produces functionalized silicon nanoparticles and quantum dots for various applications. Notably, its products enhance the energy density of lithium-ion batteries by 30-40%, making them suitable for electric vehicles, consumer electronics, and IoT devices, all without compromising battery life or increasing costs. Additionally, Advano's technology is applied in CO2 carbon capture, super hydrophobic coatings, and printable electronics, serving industries such as telecommunications.
Rocket Lab Ltd. specializes in designing and manufacturing rocket and space systems, focusing on low-cost and efficient payload deployment. Founded in 2006 and based in Auckland, New Zealand, the company offers a variety of technologies, including carbon composite materials, thermal protection products, recovery systems, propulsion systems, and electronic systems for avionics and communication. Its flagship orbital launch vehicle, Electron, aims to transform the space industry by providing dedicated, high-frequency launches tailored for the growing small satellite market. Rocket Lab's innovations are geared towards making space access more affordable and accessible.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. The company integrates automation, machine learning, and genomics to enhance its platform, which aids in optimizing microbial strains and improving the efficiency of production processes. By leveraging big data and artificial intelligence, Zymergen collaborates with clients to engineer novel molecules from microbes, thereby advancing product development. Founded in 2013 and headquartered in Emeryville, California, Zymergen also has offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, enabling it to serve a global clientele effectively.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. The company integrates automation, machine learning, and genomics to enhance its platform, which aids in optimizing microbial strains and improving the efficiency of production processes. By leveraging big data and artificial intelligence, Zymergen collaborates with clients to engineer novel molecules from microbes, thereby advancing product development. Founded in 2013 and headquartered in Emeryville, California, Zymergen also has offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, enabling it to serve a global clientele effectively.
Nervana is a technology company founded in 2014 and headquartered in San Diego, California. It specializes in machine learning and artificial intelligence, offering a software-as-a-service platform that enables businesses to develop custom deep learning applications. The company's flagship product, Nervana Cloud, provides a comprehensive software solution that utilizes deep learning techniques to facilitate the creation of intelligent applications. Founded by experts in various fields, including machine learning, neuroscience, and chip design, Nervana aims to simplify and scale the use of brain-inspired algorithms in technology development.
Atomwise, Inc. specializes in deep learning artificial intelligence technology aimed at small molecule drug discovery. The company leverages its proprietary AI platform, AtomNet, which contains over 16 billion molecules for virtual screening, to enhance the speed and accuracy of drug discovery processes. This technology employs a statistical approach to predict the binding of small molecules to proteins, aiding in drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise collaborates on numerous projects each year with major pharmaceutical and agrochemical companies, as well as over 200 universities and hospitals across 40 countries. Founded in 2012 and based in San Francisco, Atomwise was previously known as Chematria, Inc. before rebranding in 2015.
Bagaveev Corporation is a nanosatellite launcher company based in Half Moon Bay, California, incorporated in 2013. The company specializes in designing, developing, and testing pressure-fed, 3D-printed rocket engines, including aerospike engines intended for both the lower and upper stages of its rocket system. This rocket, measuring 35 feet in height, is engineered to deliver 10-12 kg nanosatellites to low Earth orbit and Sun-synchronous orbit. Backed by Adam Draper's Boost accelerator and advised by Tim Draper, Bagaveev Corporation aims to advance the capabilities of nanosatellite launches through innovative rocket technology.
Omniome, Inc. is a biotechnology company based in San Diego, California, established in 2013. It specializes in developing a proprietary DNA sequencing platform that aims to deliver high accuracy in sequencing results. The company employs its Sequencing By Binding technology, which enhances nucleotide and DNA matching by utilizing the natural matching capabilities of polymerase. This innovative approach not only provides precise and rapid results but also offers a cost-effective solution, which has the potential to significantly advance cancer diagnostics. Omniome is backed by prominent life sciences venture investors and is focused on becoming a trusted leader in the field of clinical sequencing.
Bagaveev Corporation is a nanosatellite launcher company based in Half Moon Bay, California, incorporated in 2013. The company specializes in designing, developing, and testing pressure-fed, 3D-printed rocket engines, including aerospike engines intended for both the lower and upper stages of its rocket system. This rocket, measuring 35 feet in height, is engineered to deliver 10-12 kg nanosatellites to low Earth orbit and Sun-synchronous orbit. Backed by Adam Draper's Boost accelerator and advised by Tim Draper, Bagaveev Corporation aims to advance the capabilities of nanosatellite launches through innovative rocket technology.
Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. The company integrates automation, machine learning, and genomics to enhance its platform, which aids in optimizing microbial strains and improving the efficiency of production processes. By leveraging big data and artificial intelligence, Zymergen collaborates with clients to engineer novel molecules from microbes, thereby advancing product development. Founded in 2013 and headquartered in Emeryville, California, Zymergen also has offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, enabling it to serve a global clientele effectively.
Moleculo is a biotech company that focuses on developing technologies for generating long reads for genome analysis tools. The company has developed a novel DNA sequencing method that provides long and accurate reads, thereby improving the efficiency and accuracy of many existing DNA sequencing applications, enabling clients to get a range of new applications.